NMDA receptors (NMDARs) are tetrameric ligand-gated ion channels permeable to Na^+^, K^+^, and Ca^2+^, composed of 2 glycine binding GluN1 subunits and 2 glutamate binding GluN2/3 subunits (GluN2A, GluN2B, GluN2C, GluN2D, GluN3A, GluN3B).^[@R1][@R2][@R3]^

In contrast to GluN2/3 subunits, which each have specific spatial and temporal expression patterns throughout the CNS, GluN1 encoded by *GRIN1* is a ubiquitous component of the receptor.^[@R4],[@R5]^

Mutations of the NMDAR subunits are associated with a variety of different neurodevelopmental phenotypes,^[@R3]^ including intellectual disability (ID),^[@R6][@R7][@R8]^ epilepsy,^[@R9][@R10][@R13]^ and autism spectrum disorders (ASD), and different psychiatric diseases.^[@R14],[@R15]^

While several studies have focused on the phenotypic spectrum of *GRIN2A*- and *GRIN2B*-associated disorders, little is known about the clinical presentations of individuals with *GRIN1* mutations. We reviewed clinical data on individuals with *GRIN1* mutations from different research cohorts as well as from diagnostic laboratories.

In addition, we reviewed available clinical and genetic information from previously reported patients with *GRIN1* mutations. Nine heterozygous de novo mutations had previously been reported with rudimentary phenotypic information: 4 individuals were described with nonsyndromic and nonspecific ID (mental retardation, autosomal dominant 8, OMIM 614254),^[@R8],[@R16],[@R17]^ 1 individual had epileptic encephalopathy of Lennox-Gastaut type,^[@R9]^ and 4 individuals were described with severe developmental delay and associated movement disorders.^[@R18]^

Our study aimed at a comprehensive delineation of the associated phenotype and at an investigation of the functional consequences of the identified *GRIN1* mutations.

METHODS {#s1}
=======

Patients. {#s1-1}
---------

We reviewed clinical and genetic information on patients in whom *GRIN1* mutations were detected through different next-generation sequencing approaches in diagnostic and research settings including targeted panel sequencing^[@R19]^ or whole-exome sequencing (table e-1, a and b, on the *Neurology*® Web site at [Neurology.org](http://neurology.org/lookup/doi/10.1212/WNL.0000000000002740)). Depending on the availability of parental samples, the de novo status of each mutation was confirmed through conventional Sanger sequencing.

Standard protocol approvals, registration, and patient consents. {#s1-2}
----------------------------------------------------------------

Written informed consent for genetic testing was obtained for every individual. Genetic testing within research settings was approved by the Commission of Medical Ethics of the University of Antwerp, Belgium; the Ethics Committee of Western Zealand, Denmark; the Kantonale Ethikkommission Zürich, Switzerland; and additional local ethics committees of the contributing centers.

In silico prediction. {#s1-3}
---------------------

Predictions of the functional impact of identified coding variants were assessed by different in silico analysis programs (PolyPhen2, <http://genetics.bwh.harvard.edu/pph2/> and MutationTaster, <http://www.mutationtaster.org>) using the *GRIN1* transcript number ENST00000371561 (table e-2). Variants were compared to 60,706 controls of the ExAC browser (<http://exac.broadinstitute.org/>). Conservation of mutated positions was evaluated using sequence alignment of different species (figure e-1). Molecular modeling of the NMDAR subunits was performed according to Endele et al.^[@R7]^

DNA constructs, oocyte expression, and electrophysiology. {#s1-4}
---------------------------------------------------------

For *Xenopus laevis* oocyte experiments, GluN1 and GluN2B constructs and capped cRNAs were generated as described previously.^[@R11],[@R12]^ Several mutations were introduced into these constructs using the QuikChange site-directed mutagenesis kit (Stratagene; Agilent Technologies, Santa Clara, CA) and confirmed by DNA sequencing. Oocytes were isolated and maintained as described previously.^[@R20]^ Glutamate, glycine, and Zn^2+^ dose--response curves of wild-type GluN1/GluN2B and mutant NMDARs were analyzed by 2-electrode voltage clamp recording as described.^[@R21]^ Concentration--response curves and current traces shown in the figures were drawn using KaleidaGraph (Synergy Software, Reading, PA). Data represent means ± SE. Statistical significance was evaluated using a Student 2-tailed unpaired *t* test if not otherwise stated. All chemicals used were obtained from Sigma.

RESULTS {#s2}
=======

We identified 14 previously unreported patients with heterozygous *GRIN1* mutations. In 13 individuals, the mutation was confirmed to be de novo, whereas in patient 22 parental samples were not available for segregation analysis. However, given that the particular mutation in patient 22 was recurrent in 2 other patients (patients 21 and 23) and absent in large control datasets, we concluded that the mutation is pathogenic and included this patient in our analysis. In addition to these 14 novel cases, we reviewed phenotypic data of all 9 previously reported cases^[@R8],[@R9],[@R16][@R17][@R18]^ and present additional clinical information on 4 of these patients.^[@R8],[@R9],[@R16]^ Thus, we were able to collectively review the clinical data of 23 patients ([table 1](#T1){ref-type="table"}). In addition to patients with de novo *GRIN1* mutations, we identified 2 homozygous *GRIN1* mutations segregating in 2 unrelated families with severe neurodevelopmental disorders (1.1--2 and 5.1--3). In both cases, family members carrying heterozygous *GRIN1* variants were unaffected.

###### 

Phenotypes of cases with *GRIN1* mutations

![](NEUROLOGY2015694455TT1)

Phenotypes associated with heterozygous de novo *GRIN1* mutations. {#s2-1}
------------------------------------------------------------------

Almost all patients carrying a de novo *GRIN1* mutation presented with profound global developmental delay, usually already apparent in the neonatal period and resulting in severe intellectual disability (21/22; 95%). (table e-1, a and b) Patients usually never acquired the ability to walk and had absent or extremely limited verbal communication skills.

Of the 21 patients in whom information regarding muscular tone could be retrieved, 15 (71%) had severe truncal and initial appendicular hypotonia. Many patients developed corticospinal signs, such as hyperreflexia (6/21; 29%) or spasticity (6/21; 29%), consistent with a diagnosis of spastic quadriparesis. The majority of patients showed choreatic, dystonic, or dyskinetic movement disorders (14/23; 61%), including oculomotor abnormalities such as oculogyric crises (5/23; 22%). Nonspecific stereotypic movements were noted in 7/21 patients (33%).

A significant proportion of patients (16/23; 70%) had epilepsy. The epilepsy phenotype of *GRIN1* mutation carriers was variable with respect to age at onset (day of life 1--11 years), seizure semiology (infantile spasms, tonic and atonic seizures, hypermotor seizures, focal dyscognitive seizures, febrile seizures, generalized seizures, status epilepticus), and the associated EEG pattern (hypsarrhythmia, focal, multifocal and generalized spikes and waves). In addition to the variability of the epilepsy phenotype, the outcome relating to the control of seizures was variable: while at least 5 patients (5/16; 31%) had therapy-resistant epilepsy, 2 patients became seizure-free or had long periods of seizure freedom on valproate (VPA), whereas 2 additional patients responded well on a combination of topiramate, levetiracetam, and clobazam or the introduction of vigabatrin and clonazepam in addition to VPA. In most other epilepsy patients, clinical data were not available or seizures were not reported as a prominent phenotype (table e-3, a and b). Given this variability, the epilepsy phenotype of *GRIN1* mutation carriers usually did not resemble specific forms of epileptic encephalopathies, which is in contrast to *GRIN2A*- and some *GRIN2B*-associated disorders.^[@R9][@R10][@R13]^

At least 8 *GRIN1* patients were diagnosed with ASD or ASD-like features (8/23; 35%), acknowledging that the severe level of ID in most patients made a separate diagnosis of ASD challenging. This is in line with previous reports in *GRIN2B*-associated disorders^[@R14]^: 4 individuals presented with aggression and self-injurious behavior or disturbed pain perception (4/23; 17%). Eight patients (8/23; 35%) had nonspecified sleep disorders. Several patients had feeding difficulties (9/23; 39%), likely due to their underlying hypotonia and spasticity, requiring tube feeding in some patients. Several patients presented with cortical visual impairment or delayed visual maturation (5/23; 22%).

MRI findings were available for review in 19 patients, and nonspecific volume loss or atrophy was seen in 11/19 (58%) patients. These MRI findings were considered insufficient to explain the presence of quadriplegia or movement disorder seen in patients. Cortical atrophy was apparent already at young ages (e.g., cases 18 at 20 months and 25 at 3 years of age) without evidence for a significant age-dependent progression.

Two patients (2/21; 10%) had a marfanoid habitus, whereas several had normal stature or growth retardation or low body weight. Microcephaly was observed in 6/23 (26%) patients. Dysmorphic features, if present, were subtle. Deep-set eyes, which were previously reported as a common feature,^[@R18]^ could not be consistently seen in our patients.

While 21/22 patients had severe ID, one previously reported patient carrying a *GRIN1* p.Glu662Lys mutation presented with a less severe phenotype.^[@R8]^ Patient 14 was able to walk independently at age 18 months and had speech delay with adequate first words at 9 months and 2-word phrases only at 5 years of age. Additionally, the patient did not present with any other comorbid conditions including epilepsy, movement disorder, and abnormalities of muscle tone or vision.

*GRIN1* mutations with recessive inheritance. {#s2-2}
---------------------------------------------

In a consanguineous family with ID and ASD, a homozygous *GRIN1* p.Arg217Trp missense variant was found in 2 affected brothers. Both parents were healthy heterozygous carriers. The variant was predicted to be pathogenic (table e-2) and was absent in ExAC controls.

In a second consanguineous family, we identified a homozygous p.Gln556\* truncation mutation in 3 siblings with severe neonatal epileptic encephalopathy. All 3 siblings died between 5 days of life and 5 months secondary to intractable seizures. Both parents were unaffected heterozygous carriers of the p.Gln556\* mutation.

Among the 110 ExAC-annotated missense and 8 truncating *GRIN1* variants, none was reported to be homozygous in 60,706 control samples.

Spectrum and clustering of *GRIN1* mutations. {#s2-3}
---------------------------------------------

All 16 different de novo mutations identified in the 23 novel and published cases are missense alterations and cluster within or in close proximity to the transmembrane domains forming the intrinsic ion channel pore of the receptor ([figure 1](#F1){ref-type="fig"}). Interestingly, this region is widely spared from genetic variation in controls and shows a high level of conservation in different species (figure e-1). In contrast, there is extensive enrichment of reported single nucleotide variants (SNV) in controls in the N-terminal domain as well as the C-terminus of *GRIN1*. De novo mutations have not been observed in either domain. The reported mutations do not allow us to assess the genetic variability of S1 and S2 ligand binding sites. However, the S1 domain contains numerous and frequent SNV but no disease-causing mutations so far, whereas S2 showed less variability with only 2 nonrecurrent SNV but one mutation ([figure 1](#F1){ref-type="fig"}). Moreover, this single mutation detected within S2 was associated with the mildest phenotype (patient 14) when compared to all other *GRIN1* de novo mutations closely related to the transmembrane domains. Five de novo mutations have been detected recurrently in independent patients within our cohort (p.Asp552Glu, p.Gly815Arg, p.Phe817Leu, p.Gly827Arg, p.Arg844Cys).

![Domains of *GRIN1* and distribution of variants\
Signal peptide (SP), the extracellular N-terminal domain, and ligand binding sites (S1, S2), the transmembrane domains (M1-4), as well as the intracellular C-terminal domain (CTD) with the proximal Ca^2+^ calmodulin binding domain (CBD). De novo mutations (red) cluster within or in very close proximity to M1-4. In addition, this region is particularly spared from nonsynonymous genetic variation according to the ExAC browser (rare/single variants, gray; repeated/frequent variants, black). The 2 homozygous *GRIN1* variants are marked in blue.](NEUROLOGY2015694455FF1){#F1}

The only mutation being far outside the transmembrane cluster is the p.Arg217Trp missense variant that was identified in a recessive family with unaffected heterozygous carriers.

Functional investigations. {#s2-4}
--------------------------

Ectopic expression of the GluN1 mutants with wild-type GluN2B subunits revealed that 4 of the mutants gave no response to up to 10 mM glutamate and glycine and were hence rated as nonfunctional (p.Gln556\*, p.Gly618Arg, p.Gly620Arg, p.Gly827Arg; n = 10, each). For all other mutants, changes in maximal inducible currents and agonist affinities were examined. Four mutations (p.Pro557Arg, p.Tyr647Ser, p.Gly815Arg, p.Phe817Leu) resulted in a highly significant reduction of agonist Imax values (*p* \< 0.001, n = 5--9; figure e-2a). Our model of the *GRIN1/GRIN2B* NMDAR^[@R11]^ predicts strong intersubunit and intrasubunit interactions between adjacent helical structures M3 and M4 for mutated positions p.Pro557, p.Tyr647, p.Gly815, p.Phe817, and p.Gly827, thereby destabilizing the quaternary structure of the receptor transmembrane domains and disturbing assembly of NMDARs. Consistent with an impaired function of *GRIN1* de novo mutations, analysis of the agonist dose-response curves for mutations p.Gly815Arg and p.Phe817Leu additionally revealed a highly significant reduction in the affinities for both glutamate and glycine (figure e-2b). For positions p.Gly618 and p.Gly620, our model predicts a location in the membrane re-entrant loop (the P-loop) of the GluN1 subunit, which determines the narrow constriction and ion selectivity of the channel. Thus, conversion of the pore residues p.Gly618 and p.Gly620 to a charged arginine side chain likely has strong impact on NMDA channel properties. Coexpression of wild-type GluN1 with mutants GluN1 p.Tyr647Ser or p.Phe817Leu resulted in intermediate effects of agonist Imax values (*p* \< 0.01, n = 5), supporting the idea of a negative impact of the substitutions on the function of hetero-oligomeric NMDARs (figure e-2c). Mutations p.Arg217Trp, p.Ala645Ser, and p.Arg844Cys generated functional receptors with agonist Imax values (*p* \> 0.05, n = 5) similar to wild-type (data not shown). Functional analysis of the missense alteration GluN1 p.Arg217Trp in the N-terminal Zn^2+^-binding domain with wild-type GluN2A subunits showed a significant increase in Zn^2+^ inhibition (figure e-2d), suggesting impaired activation in vivo due to increased tonic inhibition of *GRIN1*^*Arg217Trp*^--*GRIN2A* receptors at physiologic concentrations of Zn^2+^. However, functional analysis of mutations p.Ala645Ser and p.Arg844Cys revealed no significant effects on agonist Imax values or affinity, suggesting that these 2 substitutions may alter NMDAR function through other mechanisms. For example, since the recurrent substitution p.Arg844Cys is located in the intracellular Ca^2+^-calmodulin-binding domain, disturbed interactions with intracellular proteins may impair receptor function. Our analyses of de novo mutations are consistent with a dominant-negative effect resulting in a significant loss of receptor function.

DISCUSSION {#s3}
==========

We reviewed 14 novel and 9 previously published individuals carrying heterozygous *GRIN1* de novo mutations associated with neurodevelopmental phenotypes.

Profound developmental delay associated with severe ID and lack of speech development are predominant features, and muscular hypotonia leading to spastic quadriplegic cerebral palsy, hyperkinetic movement disorders including dystonia and chorea, and oculomotor abnormalities as well as cortical visual impairment appeared to be recurrent findings in individuals with *GRIN1* encephalopathy. While some of these features can be seen in other genetic epileptic encephalopathies such as *SCN2A* and *SCN8A* encephalopathies (OMIM 613721, 600702), these findings are novel in the context of NDMAR encephalopathies. Seizures occurred in about two-thirds of cases. However, there was no obvious epilepsy pattern with respect to age at onset, seizure semiology, EEG features, or outcome. Furthermore, the frequency of epilepsy in *GRIN1* patients may be an overestimate due to inclusion of a high proportion of epilepsy patients in the screening cohorts.

*GRIN1* encodes GluN1 and autoantibodies primarily targeting an epitope within the N-terminal domain of GluN1 result in the increasingly recognized clinical entity of NMDAR encephalitis.^[@R22],[@R23]^ NMDAR encephalitis is an acute paraneoplastic or parainfectious neurologic disorder where decay of NMDARs is considered to be the underlying pathomechanism, partially paralleling the pathophysiology of GluN1 loss of function seen in our patients with *GRIN1* encephalopathy. While the acuity of the clinical presentation is vastly different, with NMDAR encephalitis presenting as an acute acquired condition while *GRIN1* encephalopathy is a chronic neurodevelopmental disease, we would like to emphasize a shared group of symptoms including choreatic and dystonic movements, seizures, and sleep cycle dysregulation, which we observe in our patient cohort. Further research will be able to address the question whether the *GRIN1* encephalopathy phenotype is specific enough to hypothesize a spectrum of NMDAR impairment in human disease.

*GRIN1* de novo mutations cluster within or in direct proximity to the transmembrane domains of *GRIN1* ([figure 1](#F1){ref-type="fig"}). These regions are largely spared from genetic variation, underlining the crucial importance of these domains. The sole mutation outside this cluster is p.Arg217Trp, which appears to be only pathogenic when present homozygously and thus might mediate its effect through different effects compared to the heterozygous variants near the transmembrane domains.

All reported de novo mutations are missense variants. In contrast to *GRIN2A* and *GRIN2B*, heterozygous truncation of *GRIN1* apparently does not result in a neurologic phenotype. Furthermore, both deletions encompassing *GRIN1* as well as truncating or splice-site variants are seen in control databases, suggesting that haploinsufficiency in *GRIN1*, albeit rare, is tolerated in the human population.

In addition to 16 different heterozygous de novo mutations, we describe 2 recessive *GRIN1* mutations. The homozygous loss-of-function p.Arg217Trp mutation segregated with severe ID, ASD, and movement disorders in 2 affected siblings in a consanguineous family (family 1), and a homozygous p.Gln556\* truncation mutation was found in 3 individuals with fatal epileptic encephalopathy in family 5 ([table 1](#T1){ref-type="table"}).

As the NMDAR obligatorily contains 2 GluN1 subunits, truncation or lack of both *GRIN1* alleles would result in a knock-out and complete deprivation of the NMDAR. The almost continuous seizure activity with suppression-burst EEG and early death of all 3 affected siblings in family 5 underlines the vital role of GluN1 in NMDAR functioning.

This disease mechanism as well as functional data point towards a dominant-negative effect. In contrast to the gain of function frequently detected in other *GRIN*-associated neurodevelopmental disorders,^[@R11],[@R12]^ *GRIN1* de novo mutations p.Pro557Arg, p.Ser560dup, p.Gly618Arg, p.Gly620Arg, p.Tyr647Ser, p.Gly815Arg, p.Phe817Leu, and p.Gly827Arg result in a loss of function.

The extent and nature of the loss of NMDAR function due to de novo *GRIN1* mutations corresponded only marginally to the uniformly severe phenotypes. One possible explanation for this lack of genotype--phenotype correlation may be effects on the subunit composition or trafficking of the NMDAR that potentially lead to a shared secondary mechanism compensating GluN1 defects independent of the individual severity of the respective *GRIN1* mutation eventually escaping visualization using standard artificial in vitro models.

Given the multiple observations of heterozygous de novo *GRIN1* loss-of-function mutations, *GRIN1*-associated disorders are a recurrent cause of severe and complex neurodevelopmental disorders. Additionally, homozygous *GRIN1* mutations segregating with severe phenotypes display phenotypic overlap with individuals carrying heterozygous *GRIN1* de novo mutations. This observation blurs the borders of autosomal-dominant and autosomal-recessive inheritance. The constellation of severe ID and associated findings including prominent hypotonia, movement disorders, oculogyric crises, cortical visual impairment or blindness, absent speech, behavioral issues, sleep disorder, and seizures may allow for a phenotypic differentiation from other frequent forms of severe ID. Together with the catastrophic phenotype seen in homozygous truncation mutation carriers, our findings underscore the essential role of the NMDAR subunits in neurodevelopment.

Supplementary Material
======================

###### Data Supplement

Supplemental data at [Neurology.org](http://neurology.org/lookup/doi/10.1212/WNL.0000000000002740)
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NMDAR
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